← All stocks

Indaptus Therapeutics, Inc.

INDP Net buying

CIK 0001857044 #3996 in the set updated 21 Sep 2026

Bought (120 mo)

$492.87K

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$100.04K

$0.00 on a plan · $0.00 straight out of an exercise

Sold at will

$100.04K

2 of 2 sales

Net

+$392.83K

+$392.83K against sales at will

By person

7 insiders · 18 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Meckler Jeffrey A

Co-Chief Executive Officer

$273.57K (8)

—

+$273.57K

229,929

$538.03K

—

Anderson Glen R.

10% owner

$216.39K (3)

—

+$216.39K

1,190,400

$2.79M

+9.5%

Newman Michael James

CSO and Director

—

$100.04K (2)

−$100.04K

1,469,430

$3.44M

+2.2%

Litchev Boyan Vesselinov

Chief Medical Officer

$2.52K (4)

—

+$2.52K

1,150

$2.69K

—

Linscott Walt Addison

Chief Operating Officer

$393.00 (1)

—

+$393.00

54,426

$127.36K

—

Sassi Nir

Chief Financial Officer

—

26,758

$62.61K

—

Ben-Tzvi Avraham

Director

—

25,100

$58.73K

+25,000%

No percentages here. This company's share count has moved by a factor of 120.4 over the window, from 1,106,529 to 133,242,324 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Individual transactions

Nothing of that kind in this period.

What was left out

Form 4 filings counted 84

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 0

Sales straight out of an exercise 0

Sales at will 2

Transactions with no price 0

Shares from compensation/vesting 508,553

Sales filed before the plan box existed 2

History held since 6 Aug 2021